Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
about
Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@en
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@nl
type
label
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@en
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@nl
prefLabel
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@en
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@nl
P2093
P2860
P50
P1433
P1476
Carfilzomib-dexamethasone vers ...... of the phase 3 ENDEAVOR study.
@en
P2093
Andrew Spencer
Douglas Joshua
Karim S Iskander
Shibao Feng
Wee-Joo Chng
P2860
P356
10.1080/10428194.2017.1376743
P50
P577
2017-09-22T00:00:00Z